^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ONKT101

    i
    Other names: ONKT101
    Associations

    News

    Trials
    Company:
    Avectas, ONK Therap
    Drug class:
    CD19 inhibitor, TRAIL R2 agonist
    Related drugs:
    Associations

    News

    Trials
    3years
    Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
    Finally, we consider the broader landscape of competing immunotherapeutic approaches to AML treatment. In doing so we evaluate the innate potential, status and remaining barriers for CAR-NK based AML immunotherapy.
    Review • Journal
    |
    CD19 (CD19 Molecule)
    |
    ONKT101